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A B S T R A C T
Background
The measurement of severity and control of asthma in both children and adults can be based on subjective or objective measures. It
has been advocated that fractional exhaled nitric oxide (FeNO) can be used to monitor airway inflammation as it correlates with some
markers of asthma. Interventions for asthma therapies have been traditionally based on symptoms and/or spirometry.
Objectives
To evaluate the efficacy of tailoring asthma interventions based on exhaled nitric oxide in comparison to clinical symptoms (with or
without spirometry/peak flow) for asthma related outcomes in children and adults.
Search methods
We searched the Cochrane Airways Group Specialised Register of Trials, the Cochrane Central Register of Controlled Trials (CEN-
TRAL), MEDLINE, EMBASE and reference lists of articles. The last search was completed in February 2009.
Selection criteria
All randomised controlled comparisons of adjustment of asthma therapy based on exhaled nitric oxide compared to traditional methods
(primarily clinical symptoms and spirometry/peak flow).
Data collection and analysis
Results of searches were reviewed against pre-determined criteria for inclusion. Relevant studies were independently selected in duplicate.
Two authors independently assessed trial quality and extracted data. Authors were contacted for further information with response
from one.
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Main results
Two studies have been added for this update, which now includes six (2 adults and 4 children/adolescent) studies; these studies differed
in a variety of ways including definition of asthma exacerbations, FeNO cut off levels, the way in which FeNOwas used to adjust therapy
and duration of study. Of 1053 participants randomised, 1010 completed the trials. In the meta-analysis, there was no significant
difference between groups for the primary outcome of asthma exacerbations or for other outcomes (clinical symptoms, FeNO level
and spirometry). In post-hoc analysis, a significant reduction in mean final daily dose inhaled corticosteroid per adult was found in
the group where treatment was based on FeNO in comparison to clinical symptoms, (mean difference -450 mcg; 95% CI -677 to -
223 mcg budesonide equivalent/day). However, the total amount of inhaled corticosteroid used in one of the adult studies was 11%
greater in the FeNO arm. In contrast, in the paediatric studies, there was a significant increase in inhaled corticosteroid dose in the
FeNO strategy arm (mean difference of 140 mcg; 95% CI 29 to 251, mcg budesonide equivalent/day).
Authors’ conclusions
Tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide in comparison to clinical symptoms was carried out in
different ways in the six studies and found only modest benefit at best and potentially higher doses of inhaled corticosteroids in children.
The role of utilising exhaled nitric oxide to tailor the dose of inhaled corticosteroids cannot be routinely recommended for clinical
practice at this stage and remains uncertain.
P L A I N L A N G U A G E S U M M A R Y
Tailoring asthma interventions based on exhaled nitric oxide
In this review involving 1010 adults and children with asthma, we found that tailoring the dose of inhaled corticosteroids based on
exhaled nitric oxide (compared to clinical symptoms with or without spirometry/peak flow) was beneficial in reducing the final (but not
the overall) daily inhaled corticosteroid doses in adults. However in children inhaled corticosteroid dose was increased when exhaled
nitric oxide guided strategy was used. There was no difference between groups in other asthma outcomes (exacerbations, spirometry,
FeNO or symptom control). Thus tailoring the dose of inhaled corticosteroids based on exhaled nitric oxide cannot be routinely
advocated.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Patient or population: Adults and children with asthma
Settings:
Intervention: Tailored intervention based on FeNO
Comparison: Intervention based on clinical symptoms
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Intervention based on
clinical symptoms
Tailored intervention
based on FeNO
Number of subjects who
had one or more exac-
erbations over the study
period in adults
(follow-up: 52 weeks)
30 per 100 27 per 100
(12 to 51)
OR 0.85
(0.3 to 2.43)
197
(2)
⊕⊕⊕©
moderate1
Number of subjects who
had one or more exac-
erbations over the study
period in children and
adolescents
(follow-up: 26-52 weeks)
36 per 100 30 per 100
(24 to 36)
OR 0.75
(0.55 to 1.01)
782
(3)
⊕⊕⊕©
moderate2,3,4
Number of exacerba-
tions per 52 weeks in
adults
(follow-up: mean 52
weeks)
The mean number of ex-
acerbations per 52 weeks
in adults in the control
groups was
0.66
The mean Number of ex-
acerbations per 52 weeks
in adults in the interven-
tion groups was
0.14 lower
(0.41 lower to 0.12
higher)
197
(2)
⊕⊕⊕©
moderate1
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Number of exacerba-
tions per 52 weeks
in children and adoles-
cents
(follow-up: mean 52
weeks)
The mean number of ex-
acerbations per 52 weeks
in children and ado-
lescents in the control
groups was
0.84
The mean Number of ex-
acerbations per 52 weeks
in children and adoles-
cents in the intervention
groups was
0.18 lower
(0.42 lower to 0.06
higher)
546
(1)
⊕⊕⊕©
moderate3,4
ICS dose at final visit in
adults
(follow-up: 52 weeks)
The mean ics dose at fi-
nal visit in adults in the
control groups was
1088 mcg/day (budes-
onide equivalent)
The mean ICS dose at fi-
nal visit in adults in the
intervention groups was
450 lower
(677 to 223 lower)
197
(2)
⊕⊕⊕©
moderate5
ICS dose at final visit
in children and adoles-
cents
(follow-up: 26-52 weeks)
The mean ics dose at fi-
nal visit in children and
adolescents in the control
groups was
804 mcg/day (budes-
onide equivalent)
The mean ICS dose at fi-
nal visit in children and
adolescents in the inter-
vention groups was
140 higher
(29 to 251 higher)
777
(3)
⊕⊕©©
low3,6,7
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidance
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Confidence intervals are wide and include clinically important benefit and harm
2 One study (deJongste 2008) design was open-label which may have introduced bias.
3 Studies reported technical difficulties with FeNO analysers as reported in risk of bias table.
4 Medication increased prior to commencement of study.
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5 In one study the overall dose of ICS was higher with FeNO based interventions even though the final ICS dose was lower
6 One study presented in these results was single blinded with intervention arm analysing FeNO only.
7 Final inhaled corticosteroid doses were quite varied. With one study having particularly high doses.
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B A C K G R O U N D
The severity and control of asthma in both children and adults can
be based on subjective or objective measures. Subjective measures
usually involve a series of questions used for clinical assessment,
diary cards and quality of life questionnaires. Traditional objective
measures include peak flow monitoring, spirometry and degree of
airway hyper-responsiveness (AHR) (Zacharasiewicz 2005). Based
on current data on airway inflammation and asthma, exhaled nitric
oxide (FeNO) is advocated as a monitoring marker for asthma
control in adults and children. Some have suggested use of an
algorithm that is based on FeNO to tailor asthma medications
(Szefler 2005) instead of the traditional use of clinical symptoms
and simple spirometry.
In asthma, inflammation can be eosinophilic or non-eosinophilic
(Douwes 2002). Corticosteroids which targets eosinophilic in-
flammation is a key medication in the management of asthma.
Assessing airway inflammation by quantitative measurements of
eosinophilic inflammation, instead of subjective data, potentially
allows the physician to tailor personal asthma interventions. In
patients with eosinophilic inflammation the use of inhaled corti-
costeroids (ICS), reduces exacerbations and improves symptoms
and asthma control. Eosinophilic inflammation can be measured
by cell count in sputum or FeNO level. FeNO correlates with
other markers of asthma e.g.. eosinophilia in induced sputum
(Jatakanon 1998) and bronchial reactivity in non-steroid treated
subjects (Dupont 1998). However, induced sputum and sputum
analysis is labour intensive andnotwidely available in non-research
laboratories. Hypertonic saline, used to induce sputum may also
temporarily increase asthma symptoms. Measures of FeNO thus
confer some advantage over measurements of sputum eosinophils.
However it does not provide any data on non-eosinophilic inflam-
mation and the equipment required to measure FeNO is relatively
expensive.
A systematic review evaluating the efficacy of tailoring asthma
interventions based on exhaled nitric oxide in comparison with
the traditional reliance upon clinical symptoms of asthma (with
or without spirometry/peak flow) will be useful to guide clinical
practice.
O B J E C T I V E S
To evaluate the efficacy of tailoring asthma interventions based
on exhaled nitric oxide in comparison to clinical symptoms (with
or without spirometry/peak flow) for asthma related outcomes in
children and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing adjustment of asthma
medications based on exhaled nitric oxide levels in comparison to
clinical symptoms (with or without spirometry/peak flow).
Types of participants
Children and adults with ’classical asthma’.
Exclusion criteria: eosinophilic bronchitis, asthma related to an
underlying lung disease such as bronchiectasis and chronic ob-
structive airway disease, or diagnostic categories such as ’cough
variant asthma’ and ’wheezy bronchitis’ where controversies exist.
Types of interventions
All randomised controlled comparisons of adjustment of asthma
therapy based on exhaled nitric oxide compared to clinical symp-
toms (with or without spirometry/peak flow). Trials that included
the use of other interventions were included if all participants had
equal access to such interventions.
Types of outcome measures
Attempts were made to obtain data on at least one of the following
outcome measures:
Primary outcomes
Asthma exacerbations during follow-up, or exacerbation rates.
Secondary outcomes
1. Objective data,
2. Symptom based data,
3. Medications.
The proportions of participants and the mean clinical improve-
ment were determined using the following hierarchy of assessment
measures (i.e. where two ormore assessment measures are reported
in the same study, the outcome measure that is listed first in the
hierarchy was used);
i) Hospitalisation, acute presentations to an emergency facility for
asthma;
ii) Rescue courses of oral corticosteroids;
iii) Symptomatic (Quality of life, Likert scale, asthma diary, visual
analogue scale) - assessed by the patient (adult or child);
iv) Symptomatic (Quality of life, Likert scale, asthma diary, visual
analogue scale) - assessed by the parents/carers;
v) Symptomatic (Likert scale, visual analogue scale) - assessed by
clinicians;
vi) Indices of spirometry, peak flow, airway hyperresponsiveness;
and
vii) Beta-agonist used.
Dose of inhaled corticosteroid used was also described as a post-
hoc analysis
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Search methods for identification of studies
Trials were identified from the following sources:
1. The Cochrane Airways Group Specialised Register of Trials
2. The Cochrane Central Register of Controlled Trials (CEN-
TRAL) Issue 4, 2008
3. MEDLINE (1966 to February 2009). Topic search strategy
combined with the RCT search filter as outlined in the Airways
Group module.
4. OLDMEDLINE (1950 to 65). Topic search strategy combined
with the RCT search filter as outlined in the Airways Group mod-
ule.
5. EMBASE (1980 to February 2009). Topic search strategy com-
bined with the RCT search filter as outlined in the Airways Group
module.
6. The list of references in relevant publications.
7. Written communication with the authors of trials included in
the review.
Searches for the electronic databases were based on the following
terms:
“asthma” AND (“exhaled nitric oxide” OR “FeNO” OR “FeNO”
OR “airway inflammation”) all as (textword) or (MeSH )
For the full search strategies see Appendix 1.
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, the literature search was
reviewed independently in triplet (HP reviewed all and two sets of
reviewers: AL; AK paired with CT) to identify potentially relevant
trials for full review. Searches of bibliographies and texts were
conducted to identify additional studies. From the full text using
specific criteria, the same sets of reviewers independently selected
trials for inclusion. There was no disagreement although it was
planned that disagreementwould have been resolved by third party
adjudication.
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the fol-
lowing information recorded: study setting, year of study, source
of funding, patient recruitment details (including number of eli-
gible subjects), inclusion and exclusion criteria, other symptoms,
randomisation and allocation concealment method, numbers of
participants randomised, blinding (masking) of participants, care
providers and outcome assessors, dose and type of intervention,
duration of therapy, co-interventions, numbers of patients not fol-
lowed up, reasons for withdrawals from study protocol (clinical,
side-effects, refusal and other), details on side-effects of therapy,
and whether intention-to-treat analyses were possible. Data was
extracted on the outcomes described previously and data from in-
cluded studies was double entered into RevMan 5.0 formeta-anal-
ysis. Initial attempts to contact the corresponding authors were
not successful, but further information was made available by one
author from a new paper de Jongste 2009 for this update.
Assessment of risk of bias in included studies
Studies included in the review underwent quality assessment and
entered into Risk of Bias table.Four components were assessed:
1. Adequate sequence generation.
2. Allocation concealment.
3. Blinding. Classified
4. Free of other bias.
Measures of treatment effect
For the dichotomous outcome variables of each individual study,
relative and absolute risk reductions were calculated using a mod-
ified intention-to-treat analysis when the outcome event is a ben-
eficial event. When the event is non-beneficial event (such as ex-
acerbation), “treatment received” analysis was utilised. A modified
intention-to-treat analysis assumes that participants not available
for outcome assessment have not improved (and probably repre-
sents a conservative estimate of effect). An initial qualitative com-
parison of all the individually analysed studies examined whether
pooling of results (meta-analysis) was reasonable. This took into
account differences in study populations, inclusion/exclusion cri-
teria, interventions, outcome assessment, and estimated effect size.
Data synthesis
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest were included in the sub-
sequent meta-analyses. The summary weighted risk ratio and
95% confidence interval (fixed effects model) were calculated
(Cochrane statistical package, RevMan 5.0). For Rate Ratios of
common events whereby one subject may have more than one
event, GIVwas utilised. The Rate Ratios were taken from the pub-
lished papers and the standard errors were calculated from confi-
dence intervals or P values published in the papers. It was planned
for cross-over studies, mean treatment differences would be cal-
culated from raw data, extracted or imputed and entered as fixed
effects generic inverse variance (GIV) outcome, to provide sum-
mary weighted differences and 95% confidence intervals. Num-
bers needed to treat (NNT) were calculated from the pooled OR
and its 95% CI applied to a specified baseline risk using an online
calculator (Cates 2003). The outcome indices were assumed to
be normally distributed continuous variables so the mean differ-
ence in outcomes could be estimated (weighted mean difference).
If studies reported outcomes using different measurement scales,
the standardised mean difference was estimated. Any heterogene-
ity between the study results was described and tested to see if it
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reached statistical significance using a chi-squared test. The 95%
confidence interval estimated using a random effects model was
included whenever there are concerns about statistical heterogene-
ity. Heterogeneity is considered significant when the P value is
<0.10 (Higgins 2005).
Subgroup analysis and investigation of heterogeneity
An a priori sub-group analysis was planned for
a) adults vs children
It was planned that sensitivity analyses be done to assess the impact
of the potentially important factors on the overall outcomes:
a) variation in the inclusion criteria;
b) differences in the medications used in the intervention and
comparison groups;
c) analysis using random effects model;
d) analysis by “strategy received”;
e) analysis by “intention-to-treat”.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
From the 2006 searches, the Airways Group specialised register/
search identified 1278 potentially relevant titles. After assessing
the abstracts, 20 papers were obtained for consideration to be
included into review, 4 papers were included. From 2009 searches,
52 additional abstracts were identified, 2 fulfilled the inclusion
criteria..
Included studies
Six studies were included (see table “Characteristics of included
studies”), four were uni-centre studies (Fritsch 2006; Pijnenburg
2005; Shaw 2007; Smith 2005) and two were multi-centred (de
Jongste 2009, Szefler 2008). Four studies were in children or ado-
lescents (de Jongste 2009, Fritsch 2006; Pijnenburg 2005, Szefler
2008), one with adult patients (Shaw 2007) and one combining
adolescents and adults (Smith 2005). Two studies were double
blind, parallel groups (Pijnenburg 2005, Szefler 2008) whereas
four were single blind, parallel groups (de Jongste 2009, Fritsch
2006; Shaw 2007; Smith 2005). All were published in English.
In all studies (de Jongste 2009; Fritsch 2006; Pijnenburg 2005;
Shaw 2007; Smith 2005; Szefler 2008) asthma management were
based on either clinical strategy/symptoms (control arm) or ex-
haled nitric oxide, with or without taking the symptoms into ac-
count (intervention arm). The management of the control arm
in the studies differed. In de Jongste 2009 treatment was based
on symptom score which was sent by electronic diary every 3
weeks. One study, Fritsch 2006 based their treatment decision
on symptoms, use of short acting beta-2-agonists and lung func-
tion. Pijnenburg 2005 used symptom scores from diary cards to
guide their decision on treatment; it was a cumulative score for
the 2 weeks prior to each visit. Shaw 2007, used the British Tho-
racic Society asthma guidelines to base their treatment decisions
which included traditional assessment of symptoms (using val-
idated Juniper asthma control questionnaire). Smith 2005 used
asthma symptoms, nighttime waking, bronchodilator use, varia-
tion in peak expiratory flow rate in previous 7 days and FEV1.
Subjects had their asthma management based on standard treat-
ment as per the guidelines of National Asthma Education and Pre-
vention Program (NAEPP) in Szefler 2008.
The intervention arm in all 6 studies, although primarily based on
FeNO level, differed in the cut off for FeNO for change in therapy.
In de Jongste et al’s study and Fritsch et al’s study, anti-inflam-
matory treatment was based on keeping FeNO below 20 ppb. In
Pijnenburg et al’s study, medication was adjusted to keep FeNO
less than 30 ppb. Shaw et al’s study aimed at keeping FeNO below
26 ppb with a minimum dose of anti-inflammatory treatment. In
Smith et al’s study, medications were based on maintaining FeNO
less than 15 ppb at a flow rate of 250 ml per second, which the
authors found to be equivalent to 35 ppb at a flow rate of 50 ml
per second. Szefler et al used a combination of different levels of
FeNO and symptoms with control level of no anti-inflammatory
treatment changes if FeNo was less than 20 ppb. All other studies
utilised a single cut off for FeNO and none of the studies took
into account the presence of atopy.
The measurement of FeNO was different among studies. All but
one study (de Jongste 2009) was a hospital based FeNO mea-
surement. De Jongste used a portable at home exhaled nitric ox-
ide analyser. Four studies (Fritsch 2006, Pijnenburg 2005, Shaw
2007, Szefler 2008) were performed in accordance to ATS/ERS
guidelines for measuring FeNO (flow rate 50mL/s). Smith et al
used a flow rate of 250mL/s.
The follow up of the six studies also differed: one of the studies de
Jongste 2009 had a duration of 30 weeks with treatment poten-
tially being altered every 3 weeks; (Fritsch 2006) ran for 6 months
with the participants being assessed in 6week intervals; Pijnenburg
2005 ran for twelve month duration with three monthly visits;
Shaw 2007 had a study duration of twelve months with partici-
pants being assessed 10 times;Smith 2005 had a study duration
for a maximum of 2 years, with phase 1 running between 3 and
12 months and phase 2 having 6 visits in 12 months; and Szefler
2008 ran for 46 weeks with scheduled visits every 6 to 8 weeks
Exacerbations were defined differently in each included study. An
exacerbation was defined as: emergency visit, hospitalization or
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prednisolone course in de Jongste 2009. In Fritsch 2006 study
asthma exacerbations were defined by 4 parameters: oral steroid
courses, and/or off-scheduled visit because of asthma symptoms
over the past 4 weeks, and/or increase of asthma symptoms from
a symptom score 0 or 1 to a symptom score 2 and/or decline
of FEV1 (L) more than 10% compared to the previous visit.
Pijnenburg 2005 defined an exacerbation as a deterioration in
symptoms requiring oral prednisone course. Shaw 2007 also used
a definition of an increase in symptoms requiring oral steroids or
antibiotics. Smith 2005 defined exacerbations as minor or major;
a minor exacerbation was defined as a daily asthma score of 2 or
more on 2 ormore consecutive days, whereas a major exacerbation
was a daily asthma score of 3 or more on 2 or more consecutive
days. Szefler 2008 combined admissions to hospital, unscheduled
visits and oral prednisone use to define an exacerbation in their
study.
Two studies were in adults (Smith 2005, Shaw2007) and four chil-
dren/adult studies (Fritsch 2006, Pijnenburg 2005, Szefler 2008,
de Jongste 2009). We classified studies into children/adolescent
studies based on the mean age reported as opposed to the entry
criteria. Thus although Szefler 2008 study’s entry criteria included
young adults (up to 20 years), the mean age of the participants
were 14·4 years (IQR 13-16) and hence included in the children/
adolescent analysis.
Risk of bias in included studies
Figure 1
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
Allocation concealment was unclear in 5 studies (de Jongste 2009;
Fritsch 2006; Pijnenburg 2005; Shaw 2007; Smith 2005). Only
two studies (Pijnenburg 2005; Szefler 2008) was double blinded.
In 3 studies (Shaw 2007; Smith 2005; Szefler 2008) the outcome
assessor was blinded. In de Jongste 2009 there was no blinding,
the FeNO group only had FeNO levels assessed. The final study
(Fritsch 2006) was unclear in their blinding. All 6 studies (de
Jongste 2009; Fritsch 2006; Pijnenburg 2005; Shaw 2007; Smith
2005; Szefler 2008) reported on the progress of all randomised
subjects. Five studies (de Jongste 2009; Fritsch 2006; Pijnenburg
2005; Smith 2005; Szefler 2008) were able tomeasure outcomes in
>90% of randomised participants. Shaw 2007 was able to measure
outcomes in 80-90% of the participants who were randomised. .
Effects of interventions
See: Summary of findings for the main comparison
The six studies ( de Jongste 2009; Fritsch 2006; Pijnenburg 2005;
Shaw 2007; Smith 2005; Szefler 2008) included 1053 randomised
participants with 1010 completing the trials.
Adults
Of the 215 adult participants whowere randomised in Smith 2005
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and Shaw 2007, 197 completed the trials.
ASTHMA EXACERBATIONS (Outcome 1)
Both adult papers (Shaw 2007; Smith 2005) used asthma exacer-
bations as the primary outcome and both described a reduction
in various aspects of asthma exacerbations in the arm that utilised
treatment based on exhaled nitric oxide (FeNO) when compared
to the clinical symptom arm (control arm whereby treatment was
based primarily on clinical symptoms). Both adult studies reported
their FeNO group experienced fewer exacerbations than the clin-
ical symptom group but the difference between groups was not
significant.
Outcomes are described below
1.1.1 Number of subjects who had one or more exacerbations
(as defined by the author) over the study period
Figure 2
Figure 2. Forest plot of comparison:1 Exacerbations, outcome: 1.1 Number of subjects who had one or
more exacerbations over the study period.
Combined data from the two studies showed that the number of
participants experiencing any exacerbations was not significantly
different (P=0.76) between the FeNOgroup and clinical symptom
group. Pooled OR estimate effect (randommodel) was 0.85 (95%
CI 0.30 to 2.43). There was heterogeneity between the studies, I2
= 63.9%. In the symptom control group 30 people out of 100 had
one of more exacerbations over the study period over 52 weeks,
compared to 27 (95% CI 12 to 51) out of 100 for the FeNO
group, Figure 3.
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Figure 3. In the symptom control group 30 people out of 100 had one of more exacerbations over the study
period (Adults) over 52 weeks, compared to 27 (95% CI 12 to 51) out of 100 for the FeNO group.
1.2.1 Exacerbation rates
Figure 4
Figure 4. Forest plot of comparison: 1 Exacerbations, outcome: 1.2 Exacerbation rates.
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There was also no significant difference between the groups for the
outcome of occurrence of any exacerbation in adults (MD -0.14;
95% CI -0.41 to 0.12), and there was no significant heterogeneity
between studies.
OBJECTIVE DATA (Outcome 2)
2.1.1 FEV1% predicted at final visit
Figure 5
Figure 5. Forest plot of comparison: 2 Objective data, outcome: 2.1 FEV1 % predicted at final visit
[%Predicted].
Data was only available from Smith et al which showed no signif-
icant difference between groups (MD 3.80 %Predicted; 95% CI
-4.50 to 12.10). Shaw and colleagues reported that “there was no
difference in FEV1 between the groups over the duration of the
study”, but no details were provided.
2.2.1 FeNO at final visit
Figure 6
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Figure 6. Forest plot of comparison: 2 Objective data, outcome: 2.2 FeNO at final visit.
At final visit there was no significant difference between the group’s
FeNO level, (SMD 0.03; 95% CI -0.25 to 0.31). The statistical
heterogeneity for this outcome was I2 = 44% (P=0.18), and a
random effects analysis yielded a wider confidence interval (SMD
0.03; 95% CI -0.34 to 0.41).
SYMPTOM BASED DATA (Outcome 3)
3.1.1 Symptom score
Figure 7
Figure 7. Forest plot of comparison: 3 Symptom based data, outcome: 3.1 Symptom score.
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There was no significant difference between groups for symptom
scores (SMD -0.14; 95% CI -0.42 to 0.14).
MEDICATIONS (Outcome 4)
4.1.1 Inhaled corticosteroids dose at final visit
Figure 8
Figure 8. Forest plot of comparison: 4 Medications, outcome: 4.4 ICS dose at final visit.
At final visit there was a significant difference between the group’s
inhaled corticosteroid dose (budesonide equivalent in mcg/day)
with lower doses in the group whose treatment was based on
FeNO, (MD -450.03; 95% CI -676.73 to -223.34). However
Shaw 2007 also reported an 11% increase in the total amount of
inhaled corticosteroids used during the study (95% CI; -15% to
37%).
Children and Adolescents
Of the 838 children and adolescents recruited in these studies
Szefler 2008, Pijnenburg 2005, Fritsch 2006 and de Jongste 2009,
813 completed.
EXACERBATIONS (Outcome 1)
None of the papers (de Jongste 2009; Fritsch 2006; Pijnenburg
2005; Szefler 2008) used asthma exacerbations as the primary out-
come, however they all used exacerbations as a secondary out-
come. As described above the definition of exacerbations differed
between the studies. Outcomes are described below.
1.1.2 Number of subjects who had one or more exacerbations
(as defined by the author) over the study period
Figure 2
Combination of data from the 4 studies found no significant dif-
ference between the groups (P=0.06), with 118 exacerbations in
the FeNO group versus 140 in the control group, (OR 0.75; 95%
CI 0.55 to 1.01). There was no significant heterogeneity between
the studies. In the symptom control group 36 people out of 100
had one of more exacerbations over the study period (children)
over 26-52 weeks, compared to 30 (95% CI 24 to 36) out of 100
for the FeNO treatment group, Figure 9.
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Figure 9. In the symptom control group 36 people out of 100 had one of more exacerbations over the study
period (children) over 26-52 weeks, compared to 30 (95% CI 24 to 36) out of 100 for the FeNO treatment
group.
1.2.2 Exacerbation rate
Figure 4
For this outcome, data was only available from Szefler 2008 with
no difference between the groups (MD -0.18; 95% CI -0.42 to
0.06).
OBJECTIVE DATA (Outcome 2)
2.1.2 FEV1% predicted at final visit
Figure 5
At final visit, therewas no significant difference between the groups
for FEV1% predicted (MD 1.81 %Predicted; 95% CI -0.64 to
4.25) in the meta-analysis of data from 3 studies, and there was no
significant heterogeneity. In Fritsch 2006’s study, FEV1 was the
primary outcome, but data could not be extracted. Howeverbut
they reported no significant differences between the groups.
2.2.2 FeNO at final visit
Figure 6
Combining Szefler 2008 and de Jongste 2009 data there was no
difference between the two groups final FeNO (SMD -0.02; 95%
CI -0.18 to 0.13). Data from Fritsch 2006 and Pijnenburg 2005
could not be included in meta-analysis; Fritsch 2006 described
no significant difference between groups, but Pijnenburg 2005
described that a significant change in FeNO between the groups
(ratio of geometric means, adjusted for baseline was 1.32 (95%
CI, 1.04 to 1.68), with the control arm having a higher FeNO at
the end of study.
2.3.1 Geometric mean change in FeNO from baseline (control/FeNO
level)
Figure 10
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Figure 10. Forest plot of comparison: 2 Objective data, outcome: 2.3 Geometric mean change in FeNO
from baseline (control/FeNO level).
Data from Pijnenburg et al’s and de Jongste et al’s studies using
GIV analysis, showing no significant difference between groups
(Geometric mean 1.17; 95% CI 0.98 to 1.39). Fritsch 2006 de-
scribed “the repeated measurement analysis demonstrated no sig-
nificant differences between groups with regards to FeNO”.
3.1.2 Symptom scores
Figure 7
Date combined from two studies (Pijnenburg 2005, Szefler 2008)
resulted in no significant difference between the groups for res-
piratory symptoms (SMD 0.04; 95% CI -0.11 to 0.20). Data
from de Jongste 2009 study could not be added to the meta-anal-
ysis but they described no significant difference in percentage of
symptom-free days during the whole study period between both
groups. Likewise, Fritsch 2006 described no significant differences
between the control and FeNO groups, and data could not be
included in the meta-analysis.
4.1.2 Inhaled corticosteroids dose at final visit
Figure 8
Two studies (Fritsch 2006, Pijnenburg 2005) reported the children
in the control strategy as having lower mean daily dose of inhaled
corticosteroids. Fritsch 2006 et al’s data presented doses asmedians
(and IQR) and thus data was not combined. In Fritsch study, the
daily ICS dose was 200 mcg higher in the FeNO group compared
to the control group and authors reported that this difference was
significant (P<0.01). The forest plot shows data fromPijnenburg’s,
Szefler’s and deJongste’s papers depicting a significant difference
between the groups, with higher doses of inhaled corticosteroids
in the FeNO group (MD 140.18; 95% CI 28.94 to 251.43 mcg/
day budesonide equivalent). There was, however heterogeneity in
this outcome, Chi² = 3.46, df = 2 (P = 0.18); I² = 42%. A random
effects model gave a wider confidence interval that included no
difference between the groups (MD 121.89; 95% CI -32.24 to
276.03).
Sensitivity Analyses
Sensitivity analyses could not be performed for most specified
criteria. Analysis using random effects is reported for individual
outcomes above. Using intention to treat analysis did not alter
direction or significance of events.
D I S C U S S I O N
This meta-analysis based on six studies in 1053 adults and chil-
dren (with 1010 completed), has showed that tailoring the dose
of inhaled corticosteroids based on exhaled nitric oxide (FeNO)
in comparison with usual traditional methods (based primarily on
clinical symptoms) did not significantly reduce exacerbations or
improve FEV1 or asthma symptoms. In children/adolescents there
was a trend favouring the FeNO strategy in number of partici-
pants with one or more exacerbation, but this was at the expense
of higher levels of inhaled corticosteroids. In adults, the FeNO
based strategy enabled a reduction in the final (but not the overall)
daily dose of inhaled corticosteroids .
Tailoring medications based on FeNO has been advocated in ed-
itorials (Szefler 2005). This Cochrane review has shown that the
benefits of utilising this strategy (as opposed to standard strategy
based on clinical symptoms and simple tests like FEV1) is at best
modest and could potentially be harmful with increased ICS use
in children. There was no significant difference between the two
strategies in both adult and paediatric studies in the primary out-
come of exacerbation, FEV1, FeNO levels or symptom control
scores. The only significant beneficial difference found between
groups was the final daily dose of ICS in adults. However this
finding is limited as this was a post-hoc analysis. Even though the
final ICS dose was lower at final visit, Shaw 2007 reported overall
higher doses of ICS in the FeNO based strategy through the du-
ration of study and was only lower on final visit. They related this
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to a proportion of patients who showed an elevated FeNO that
was associated with a normal eosinophil count (identified by spu-
tum eosinophil testing as a safety measure when the dose of ICS
reached 2000 mcg/day). Furthermore in children where high ICS
doses are of more concern due to potential adverse events, there
was a significant increase in ICS dose in the FeNO strategy arm
(mean difference of 140 ug (95% CI 29 to 251) of budesonide
equivalent/day). In a previous systematic review we found that
there was no significant difference in doses of ICS when asthma
treatment was based on sputum eosinophils, as opposed to clinical
symptoms (Petsky 2007).
The results of this reviewneed to be considered in light of several is-
sues. Firstly, all the studies except Szefler 2008 used a single but dif-
ferent cut-off level of FeNO to adjust ICS in the entire cohort, yet
studies have demonstrated that FeNO is significantly influenced
by atopic status (with a dose response) (Franklin 1999; Franklin
2003). In some studies, use of FeNO levels do not differentiate be-
tween children with and without asthma once atopy is taken into
account (Malmberg 2004; Prasad 2006) as atopic subjects have
elevated exhaled nitric oxide levels (Franklin 1999; Franklin 2003;
Prasad 2006). Other studies have shown that FeNO is indepen-
dently influenced by allergic rhinitis (Nordvall 2005) and a 40%
coefficient of variation between morning and evening FeNO with
no change in symptoms has been reported (Pijnenburg 2006).
None of the six included studies considered presence or severity of
atopy in their algorithm of management although some but not
all subjects were atopic. Shaw and colleagues reported that some
of their participants were atopic (62% in FeNO group, 70% in
control group). Smith et al did not describe whether their subjects
were atopic or not. ’Atopic asthma’ was an inclusion criteria for
Pijnenburg et al as defined as RAST class 2 or higher for at least 1
airborne allergan ever. Similarly all children in Fritsch et al had an
inclusion criteria of positive skin prick test or radioallergosorbent
test.
Secondly FeNO levels are also influenced by age and height
(Malmberg 2006) and are elevated even in well non-asthmatic
adults with a acute respiratory viral infection (Sanders 2004). Thus
arguably one single cut-off for the entire cohort irrespective of
significant biological influences of FeNO (such as atopy (Prasad
2006) and age (Strunk 2003) would not be appropriate. However,
how FeNO levels should be adjusted for these factors is currently
unknown.
Thirdly, the cut offs of FeNO utilised for stepping up or down
therapywas different between studies (ranging from15 to 30 ppb).
Pijnenburg et al (paediatric study) subjects had the highest mean
daily dose of ICS and subjects in this study also had quite high
FeNO at the final visit. Disconcertingly, use of FeNO strategy did
not result in a lower FeNO level at the end of trial. Smith et al
mentioned that their 15 ppb threshold is equivalent to 35 ppb at
a slower 50 ml/second flow rate.
Fourthly, tailoring interventions based on exhaled nitric oxide re-
quires a nitric oxide analyzer that needs calibration and mainte-
nance. Nitric oxide analysers are relatively expensive and adding
FeNO as a monitoring tool adds not only cost but also another
layer of complexity in asthma care. Analysers have only been ap-
proved by United States Food and Drug Administration for clin-
ical monitoring of anti-inflammatory treatment in 2003 (ATS
2005). As reported in Risk of Bias table (Figure 1) obtaining ac-
curate FeNO measurements each visit could not be obtained, ei-
ther due to a faulty analyzer (de Jongste 2009) or technical is-
sues (Fritsch 2006). Also, many aspects need to be considered
when analysing exhaled nitric oxide; this includes the timing of
spirometry (transiently reduces FeNO), food and beverage, cir-
cadian rhythm, smoking history, ambient NO and exercise (ATS
2005).
Although tests for FeNO are non-invasive and relatively easy to
obtain measurements in children (when compared with obtaining
and analysing sputum), it is not clear how to tailor the dose of
inhaled corticosteroids based on exhaled nitric oxide in compari-
son to clinical symptoms. This is in contrast to tailoring asthma
interventions based on sputum eosinophils where it is beneficial
in reducing the frequency of asthma exacerbations in adults with
asthma (Petsky 2007).
Limitations of review
This systematic review is limited to six studies with only 1010 sub-
jects completing the trials. While the studies share some common
issues, there are also significant differences, notably, the definition
of asthma exacerbation, the cut off levels for FeNOwere different,
the control strategy and the steps for tailoring medications.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The studies included in this review highlight the difficulties in-
volved in tailoring the dose of inhaled corticosteroids based on
exhaled nitric oxide, instead of primarily on clinical symptoms.
At present this approach cannot be advocated as routine clinical
practice.
Implications for research
Further RCT’s in both adults and children with groups with other
significant influences of FeNO taken into account (such as atopy)
are required. A-priori pragmatic issues of clinical practice such as
high vs low doses of ICS and to a lesser extent eosinophilic vs non-
eosinophilic asthma should be considered with costs analysis for
each sub-group. The design of future RCT’s should preferably be
parallel multi-centre studies and include outcomes of exacerba-
tions, subjective measures (such as scores for asthma control and
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quality of life) as well as objective measures (FEV1 etc). Analysis
of costs and possible adverse events of inhaled and oral corticos-
teroids would also provide additional important information.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
de Jongste 2009
Methods Prospective, open label, randomised, multicentre, parallel group study where ICS was
adjusted every 3 weeks on the basis of FeNO and symptom scores, or symptom scores
alone
4 randomised subjects (2 in FeNO group, 2 in symptom group) were excluded from
final results due to severe non-compliance (n=2), inappropriate inclusion (no allergy =
1) and 1 moving abroad
Study duration was 30 weeks.
Participants 151 children were randomised. FeNO group = 75: mean age 11.6 (SD 2.6), 46 males,
29 females. Symptom group = 72: mean age 11.8 (SD 4.3), 54 males, 18 females
Inclusion criteria: aged 6-18 years, stable mild-moderate asthma, diagnosed according
to Global Initiative for Asthma (GINA) guidelines, treatment with 200 - 1000ug of
inhaled budesonide or equivalent daily for 2 months before randomisation, and RAST
class 2 or higher or a positive skin prick test to at least one airborne allergen
Exclusion criteria: active smoking, previous admission to an intensive care unit for
asthma, and concomitant disease that might affect FeNO
Interventions All participants scored asthma symptoms in an electronic diary over 30weeks. 77 received
a portable nitric oxide (NO) analyser. Data was transmitted daily to the coordinating
centres. Patients were phoned every 3 weeks and their steroid dose was adapted according
to FeNO and symptoms (FeNO group), or according to symptoms (Symptom group)
. Children were seen at 3, 12, 21 and 30 weeks for examination, assessment of FeNO,
spirometry before and after salbutamol and recording of adverse events
Outcomes Primary outcome: Proportion of symptom-free days over the last 12 study weeks
Secondary outcomes: cumulative symptom scores, ICS dose as budesonide equivalent,
FEV1 and reversibility, FeNO0.05, prednisone courses, emergency visits, hospitalisations
for asthma, and PACQLQ scores
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information in published arti-
cle
Allocation concealment? Unclear Insufficient information of randomisation
in published article
Blinding?
All outcomes
No Open label study
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de Jongste 2009 (Continued)
Incomplete outcome data addressed?
All outcomes
Unclear “Intention-to-treat analysis was performed
for all subjects who were enrolled” however
data not shown (stated same in published
article)
Free of selective reporting? Unclear Outcomes of interest were reported incom-
pletely and were unable to be entered into
the meta-analysis
Free of other bias? No The calibration of the NIOX Minos after
the study showed drift outside the manu-
facturer’s specifications in 11 of 77 instru-
ments. The article has also reported that “a
number” of the NIOXMino’s had to be re-
placed as a risk of malfunctioning was de-
tected
Study was supported by the company (Ae-
rocrine AB, Sweden) who manufactured
the FeNO analyser
Fritsch 2006
Methods A prospective, randomised, single-blind parallel trial examining the inclusion of repeated
FeNO measurements into asthma monitoring over a period of 6 months. In the FeNO
group therapy was based on symptoms, beta-agonists use, lung function and FeNO, in
comparison to the control group where therapy was based on symptoms, beta-agonists
use and lung function only
There were 5 patients who dropped out, unsure of when these occurred
Over the 6 months, there were 5 visits in 6 weeks intervals.
Participants 52 patients entered the study. FeNO group n=22: mean age 11.3 (SD +/- 3.4), 14 males,
8 females. Control group n=25: mean age 12.1 (+/- 2.8), 14 males, 11 females.
Attended paediatric pulmonology outpatient clinic fromUniversity Children’s Hospital,
Vienna
Inclusion: Children aged between 6 -18 years with asthma diagnosis as based on Ameri-
can Thoracic Society’s criteria. Positive skin prick test (SPT) or radioallergosorbent test
(RAST>1).
Exclusion: Received oral or IV steroid treatment 4 weeks prior to their first visit
Interventions Subjects were run-in for 4 weeks. Randomised at visit 1 then outpatient visits at 6, 12,
18 and 24 weeks.
Control group: treatment based on symptoms, beta-agonists and lung function.
FeNO group: treatment based on symptoms, beta-agonists, lung function and FeNO
Outcomes Primary outcome: FEV1
Secondary outcomes: Number of exacerbations, MEF 50% predicted, better symptom
control, less short acting beta-agonists and inhaled corticosteroid dose
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Fritsch 2006 (Continued)
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information of randomisation
in published article
Allocation concealment? Unclear Insufficient information of randomisation
in published article
Blinding?
All outcomes
Unclear Single blind
Incomplete outcome data addressed?
All outcomes
Unclear Insufficient information published.
Free of selective reporting? No Primary outcome was not reported com-
pletely to allow data to be entered into
meta-analysis
Free of other bias? No FeNO measurements could not be per-
formed in 23 observations due to technical
problems
Pijnenburg 2005
Methods Randomised, double blind study evaluating whether titrating steroids on FeNO im-
proved asthma management in children. Stratified by baseline FeNO (>30 or <30ppb)
and dose of ICS (>400 or <400ug budesonide or equivalent daily dose)
Neither subjects nor physicians were aware of which group they were randomised to
There were 7 drop outs: 3 during run-in, 3 from FeNO group (1 admitted to ICU) and
1 from symptom group
The study duration was 12 months, with 5 visits at 3 monthly intervals
Participants 89 children randomised from 108 invited. FeNO group N= 39 : mean age 11.9 (SD 2.
9), 25 males, 14 females. Symptom group N= 46: mean age 12.6 (SD 2.8), 30 males,
16 females. Visiting outpatient clinic
Inclusion: use of ICS at constant dose for at least 3months preceding study, atopy defined
as RAST class 2 or higher for at least 1 airborne allergan
Interventions Children were run-in for 2 weeks, then 3 monthly visits.
FeNO group: FeNO guided ICS dosing according to predetermined algorithm.
Symptom group: symptom scores influenced ICS dosing.
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Pijnenburg 2005 (Continued)
Outcomes Primary outcome: cumulative steroid dose (sum of mean daily steroid doses of visits 1
to 5)
Secondary outcomes: mean daily symptom score, mean daily number of bronchodilator
doses taken, percentage of symptom free days during the last 4weeks of the study, number
of oral prednisone courses during the study, andprovocative dose ofmethacholine causing
a 20% fall in FEV1, FVC, FEV1 and MEF25 during final visit
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information of randomisation
in published article
Allocation concealment? Unclear Insufficient information of randomisation
in published article
Blinding?
All outcomes
Yes Parents and physician were blinded to al-
located group. The investigators provided
the physician with an ICS dose recommen-
dation according to pre-determined algo-
rithm
Incomplete outcome data addressed?
All outcomes
Yes All outcomes are reported.
Free of selective reporting? Yes Pre-specified outcomes are reported and
entered into meta-analysis
Free of other bias? Unclear No information provided on the success
in obtaining FeNO measurements at each
visit
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Shaw 2007
Methods Randomised, single blind controlled trial comparing exacerbation frequency and corti-
costeroid dosage in patients whose asthma management was based on measurements of
FeNO to a control group where management was based on the British Thoracic Soci-
ety and Scottish Intercollegiate Guidelines Network treatment guidelines. Stratified by
baseline sputum eosinophil count, baseline rescue steroid course in last year
The subjects were blinded to which group they were randomised to, at completion the
participants were asked to record which record they thought they had been assigned
There were 15 drop outs, 6 in FeNO group and 9 in control group
The study ran for 12 months and the subjects were assessed 10 times
Participants 900 adults were contacted from general practice registers of which 118 were randomised.
FeNo group N=58 : median age 50 (range 20-75), 27 males, 31 females.
Control group N=60 : median age 52 (range 24-81), 27 males, 33 females.
Attending a general practice in Leicester, UK.
Inclusion: >18 years old, diagnosis of asthma and at least one prescription for anti-asthma
medication in the past 12 months.
Exclusion: Current smokers, past smoking history of >10 pack - year or physician deter-
mines that they are poorly compliant
Interventions Subjects were seen at baseline, 2 weeks, month: 1, 2, 3, 4, 6, 8, 10 and 12.
FEV1, FeNO and Juniper asthma control score (JACS) was undertaken at each visit.
Methacholine and sputum induction was undertaken at initial visit, 6 months and at
completion of 12 months
In control group: treatment was doubled if JACS >1.57 and treatment halved if JACS
<1.57 for 2 consecutive months.
In FeNO group: FeNO>26ppb, ICS was increased. If <16ppb or <26ppb on 2 separate
occasions, treatment was decreased
Outcomes Primary outcome: Number of exacerbations.
Secondary outcomes: Total inhaled corticosteroid dose.
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information provided in pub-
lished article.
Allocation concealment? Yes Randomisation was done by an inde-
pendent individual using minimisation
method, stratified by baseline sputum
eosinophil count, FeNO and rescue steroid
courses in the last year
Blinding?
All outcomes
Yes Single blind. Participants were assessed at
completion of study regarding the group
they thought they were assigned to, 49%
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Shaw 2007 (Continued)
were unsure of which group they were
assigned, 33% correctly identified their
group, and 18% incorrectly identified their
group
Incomplete outcome data addressed?
All outcomes
Yes No missing outcome data.
Free of selective reporting? Unclear Insufficient information.
Free of other bias? Yes Measurement of FeNO was successful on
every occasion.
Smith 2005
Methods Randomised, placebo controlled, single blind study. It was a 2 phase study, with phase
1 varying in duration (3-12 months) where the dose of inhaled fluticasone was titrated
down in a stepwise manner until the optimal dose was deemed to have been achieved.
During phase 2 (12 months) optimal dose from phase 1 was continued and therapy was
stepped up if asthma control was lost
Subjects were blinded to which group they were assigned.
In phase 1 there was 16 drop outs, 13 during run in and 3 during follow up. Phase 2
had 5 drop outs during the 12 months
Participants 97 patients randomised from110 patients recruited. 46 in FeNOgroup achieved optimal
dose in phase 1 and 48 achieved optimal dose in control group
Inclusion criteria: Inhaled corticosteroids for 6 months with no dose change in previous
6 weeks.
Exclusion criteria: >4 courses of oral prednisolone in previous 12 months, admission
to hospital in the last 6 months, any intensive care admissions, or cigarette smoking
(current or past history of >10 pack-years)
Interventions Phase 1
Run-in period was for 6 weeks, after 2 weeks fluticasone 750ug/day was commenced.
Visits were every 4 weeks until optimal dose was achieved.
FeNO group: adjustment of dose of ICS was based solely to keep FeNO <15ppb at
250mL/sec.
Control group: dose adjustment based on asthma symptoms, nighttime waking, bron-
chodilator use, variation in PEFR and FEV1.
Phase 2
Visits every 2 months.
Upward adjustments made as per phase 1 but no downward adjustments would be made
from optimal dose
Outcomes Primary outcome: Frequency of exacerbation.
Secondary outcome: Mean daily dose of inhaled corticosteroids
Notes
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Smith 2005 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information of randomisation
and sequence generation in published arti-
cle
Allocation concealment? Unclear Insufficient information of randomisation
in published article
Blinding?
All outcomes
Yes Single blind. All treatment orders were ver-
ified independently by an investigator who
was blinded to treatment group
Incomplete outcome data addressed?
All outcomes
Yes Missing data has been imputed using ap-
propriate methods.
Free of selective reporting? Unclear Insufficient information provided in pub-
lished article.
Free of other bias? Unclear Nil information provided in published ar-
ticle regarding success of measuring FeNO
Szefler 2008
Methods Randomised, double-blind, parallel-group trial. Subjects had their asthma management
based on standard treatment as per the guidelines of National Asthma Education and
Prevention Program (NAEPP) or standard treatment modified on the basis of measure-
ments of fraction of exhaled nitric oxide
The subjects and physicians were not aware of their treatment assignment
The study duration was 46 weeks, with visits every 6 - 8 weeks
Twelve randomised participants were lost to follow-up before the first outcome data
was collected. During the 46-week follow-up, 17 participants in NO monitoring group
dropped out and 23 in control group
Participants 546 participants randomised from 780 patients screened. 276 assigned to NO moni-
toring group (Mean age 14.4, 146 males, 130 females), 270 assigned to control group
(Mean age 14.4, 142 males, 128 females)
Inclusion criteria: Aged between 12-20 years, diagnosed with asthma by their physician,
symptoms of persistent asthma or evidence of uncontrolled disease as defined by NAEPP
guidelines, and residents of urban census tracts in which at least 20% of households had
incomes below the federal poverty threshold
Interventions Run-in period of 3 weeks then scheduled visits every 6 to 8 weeks for 46 weeks
At each visit FeNOwas measured, days of asthma symptoms assessed, use of rescue drugs,
pulmonary function, use of health care, adherence to treatment regime and missed days
of school because of asthma
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Szefler 2008 (Continued)
Control group: Standard treatment based on the guidelines of National Asthma Educa-
tion and Prevention Program (NAEPP)
FeNO group: Standard treatment modified on the basis of measurements of fraction of
exhaled NO
Outcomes Primary outcome: Number of days with asthma symptoms.
Secondary outcomes: Admission to hospital, unscheduled visits to emergency depart-
ments or clinics, prednisone courses for asthma, asthma exacerbations, days of wheeze,
days of interference with activities, nights of sleep disruption, days of school or work
missed, and days of interruption of guardian’s activities
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Centralised block randomisation with a
block size of 10. The randomisation se-
quence was generated from a randomnum-
ber table and was stratified by site by the
use of statistical software
Allocation concealment? Yes Centralised block randomisation, with a
block size of 10. The randomisation se-
quence was generated from a randomnum-
ber table and was stratified by site by the
use of statistical software
Blinding?
All outcomes
Yes Double blind.
Incomplete outcome data addressed?
All outcomes
Unclear No reason for missing data provided.
Free of selective reporting? Unclear Insufficient information provided in pub-
lished article.
Free of other bias? No No information published on the success of
obtaining FeNOmeasurements. On enrol-
ment doses of inhaled corticosteroids were
increased by average of 219ug (95%CI
199-238) which is a large increase and
could influence the reporting of partici-
pants
FeNO: fractional exhaled nitric oxide; n: number; SD: standard deviation; IV: intravenous; FEV1: forced expiratory volume in 1
second; MEF50%: mean expiratory flow at 50%.
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Gelb 2006 Non RCT nor treatment based on eNO. Prospective study to assess eNO and spirometry to predict asthma
exacerbations
Griese 2000 Non RCT nor treatment based on eNO. Prospective study to assess eNO in comparison to symptoms,
treatment adjusted using clinical symptoms
Jatakanon 1999 Excluded as treatment not based on eNO. Randomised into two double blind, placebo controlled studies
(1 was parallel study involving 3 groups receiving either budesonide 100ug/day, budesonide 400ug/day or
placebo, the second was a crossover randomised to receive budesonide 1600ug or placebo)
Jones 2001 Non RCT. Observational study to determine if FeNO is useful in diagnosing and predicting loss of asthma
control. Subjects had ICS withdrawn until loss of control or for a maximum of 6 weeks
Jones 2002 Excluded as treatment not based on eNO. Double blind, parallel group, placebo controlled trial of 50, 100,
200 or 500ug budesonide per day
Kharitonov 1996 Non RCT. Observational study of the effect of increasing and then reducing the dose of ICS on eNO, lung
function and symptoms in patients with asthma
Kharitonov 2002 Excluded as treatment not adjusted according to eNO.Double blind, placebo controlled, parallel group study
of 100 or 400ug budesonide or placebo in subjects with mild asthma
Lim 1998 Excluded as treatment not adjusted according to eNO. Randomised, longitudinal study monitoring the effect
of increasing anti-inflammatory medication or to continue unchanged using conventional measures of lung
function, symptoms scores, medication usage and peak expiratory flow rate variability
Zacharasiewicz 2005 Non RCT. Prospective and observational study in children using non-invasive measures (eNO, induced
sputum and exhaled breath condensate) to monitor airway inflammation to result in optimal treatment
Characteristics of ongoing studies [ordered by study ID]
Petsky
Trial name or title Asthma management in children based on exhaled nitric oxide: A randomised controlled study
Methods
Participants 100 children aged <4 years randomised into FeNO group or control group. All children attend outpatient
clinics at Royal Children’s Hospital, Brisbane
Inclusion: Children aged >4 years with asthma attending a paediatric specialist clinic.
Exclusion: Presence of other cardiorespiratory illness such as cystic fibrosis, tracheomalacia, etc. Poorly com-
plaint to treatment. Inability to take inhaled corticosteroids or long acting beta-2-antagonists (LABA)
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Petsky (Continued)
Interventions Subjects will be run-in for 2 weeks. Randomised at visit 1 and then outpatient visits at month 1, 2, 3, 4, 6,
8, 10, and 12
FeNO group: Treatment based on FeNO.
Control group: Treatment based on symptoms, beta-agonists and lung functions
Outcomes Primary outcome: Exacerbation of asthma requiring oral corticosteroids and/or hospitalisation for asthma.
Secondary outcomes: FEV1, daily dose of inhaled corticosteroids
Starting date 17.01.06
Contact information Helen Petsky
Queensland Children’s Respiratory Centre
Royal Children’s
Hospital
Helen Petsky@health.qld.gov.au
Ph: 61-7-36361684
Notes
Roberts
Trial name or title No details available
Methods
Participants
Interventions
Outcomes
Starting date
Contact information
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Exacerbations
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of subjects who had
one or more exacerbations over
the study period
5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Adults 2 197 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.30, 2.43]
1.2 Children and adolescents 3 782 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.55, 1.01]
2 Mean number of exacerbations
per 52 weeks
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Adults 2 197 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.41, 0.12]
2.2 Children and adolescents 1 546 Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.42, 0.06]
Comparison 2. Objective data
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 FEV1 % predicted at final visit 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Adults 1 94 Mean Difference (IV, Fixed, 95% CI) 3.80 [-4.50, 12.10]
1.2 Children and adolescents 3 778 Mean Difference (IV, Fixed, 95% CI) 1.81 [-0.64, 4.25]
2 FeNO at final visit 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 Adults 2 197 Std. Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.25, 0.31]
2.2 Children and adolescents 2 635 Std. Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.18, 0.13]
3 Geometric mean change
in FeNO from baseline
(control/FeNO level)
2 Geometric mean (Fixed, 95% CI) 1.17 [0.98, 1.39]
3.1 Children and adolescents 2 Geometric mean (Fixed, 95% CI) 1.17 [0.98, 1.39]
Comparison 3. Symptom based data
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom score 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Adults 2 197 Std. Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.42, 0.14]
1.2 Children and adolescents 2 631 Std. Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.11, 0.20]
31Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 4. Medications
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 ICS dose at final visit 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 Adults 2 197 Mean Difference (IV, Fixed, 95% CI) -450.03 [-676.73, -
223.34]
1.2 Children and adolescents 3 777 Mean Difference (IV, Fixed, 95% CI) 140.18 [28.94, 251.
43]
Analysis 1.1. Comparison 1 Exacerbations, Outcome 1 Number of subjects who had one or more
exacerbations over the study period.
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 1 Exacerbations
Outcome: 1 Number of subjects who had one or more exacerbations over the study period
Study or subgroup FeNO strategy Control strategy Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Adults
Shaw 2007 12/52 19/51 53.4 % 0.51 [ 0.21, 1.19 ]
Smith 2005 14/46 11/48 46.6 % 1.47 [ 0.59, 3.69 ]
Subtotal (95% CI) 98 99 100.0 % 0.85 [ 0.30, 2.43 ]
Total events: 26 (FeNO strategy), 30 (Control strategy)
Heterogeneity: Tau2 = 0.36; Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.30 (P = 0.76)
2 Children and adolescents
de Jongste 2009 9/75 12/72 10.9 % 0.68 [ 0.27, 1.73 ]
Pijnenburg 2005 7/42 10/47 8.3 % 0.74 [ 0.25, 2.16 ]
Szefler 2008 102/276 118/270 80.8 % 0.76 [ 0.54, 1.06 ]
Subtotal (95% CI) 393 389 100.0 % 0.75 [ 0.55, 1.01 ]
Total events: 118 (FeNO strategy), 140 (Control strategy)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 2 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
0.1 0.2 0.5 1 2 5 10
Favours FeNO Favours control
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Analysis 1.2. Comparison 1 Exacerbations, Outcome 2 Mean number of exacerbations per 52 weeks.
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 1 Exacerbations
Outcome: 2 Mean number of exacerbations per 52 weeks
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Shaw 2007 52 0.33 (0.69) 51 0.42 (0.79) 83.3 % -0.09 [ -0.38, 0.20 ]
Smith 2005 46 0.49 (0.98) 48 0.9 (2.03) 16.7 % -0.41 [ -1.05, 0.23 ]
Subtotal (95% CI) 98 99 100.0 % -0.14 [ -0.41, 0.12 ]
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Children and adolescents
Szefler 2008 276 0.66 (1.41) 270 0.84 (1.4) 100.0 % -0.18 [ -0.42, 0.06 ]
Subtotal (95% CI) 276 270 100.0 % -0.18 [ -0.42, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
-1 -0.5 0 0.5 1
Favours FeNO Favours control
33Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Objective data, Outcome 1 FEV1 % predicted at final visit.
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 2 Objective data
Outcome: 1 FEV1 % predicted at final visit
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%Predicted] N Mean(SD)[%Predicted]IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Smith 2005 46 86.1 (18.53) 48 82.3 (22.4) 100.0 % 3.80 [ -4.50, 12.10 ]
Subtotal (95% CI) 46 48 100.0 % 3.80 [ -4.50, 12.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
2 Children and adolescents
de Jongste 2009 75 95 (14) 72 94 (14) 29.2 % 1.00 [ -3.53, 5.53 ]
Pijnenburg 2005 39 100.3 (10.62) 46 100 (13.56) 22.6 % 0.30 [ -4.84, 5.44 ]
Szefler 2008 276 96 (21.1) 270 93 (20.9) 48.2 % 3.00 [ -0.52, 6.52 ]
Subtotal (95% CI) 390 388 100.0 % 1.81 [ -0.64, 4.25 ]
Heterogeneity: Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
-50 -25 0 25 50
Favours Control Favours FeNO
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Analysis 2.2. Comparison 2 Objective data, Outcome 2 FeNO at final visit.
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 2 Objective data
Outcome: 2 FeNO at final visit
Study or subgroup FeNO strategy Control strategy
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Shaw 2007 52 24.5 (14.42) 51 27 (17.85) 52.4 % -0.15 [ -0.54, 0.23 ]
Smith 2005 46 8.6 (4.04) 48 7.6 (4.64) 47.6 % 0.23 [ -0.18, 0.63 ]
Subtotal (95% CI) 98 99 100.0 % 0.03 [ -0.25, 0.31 ]
Heterogeneity: Chi2 = 1.77, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 0.20 (P = 0.84)
2 Children and adolescents
de Jongste 2009 50 33.78 (23.81) 39 38.77 (31.44) 13.8 % -0.18 [ -0.60, 0.24 ]
Szefler 2008 276 28.5 (25.32) 270 28.5 (27.12) 86.2 % 0.0 [ -0.17, 0.17 ]
Subtotal (95% CI) 326 309 100.0 % -0.02 [ -0.18, 0.13 ]
Heterogeneity: Chi2 = 0.61, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
-1 -0.5 0 0.5 1
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Analysis 2.3. Comparison 2 Objective data, Outcome 3 Geometric mean change in FeNO from baseline
(control/FeNO level).
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 2 Objective data
Outcome: 3 Geometric mean change in FeNO from baseline (control/FeNO level)
Study or subgroup
log [Geo-
metric
mean]
Geometric
mean Weight
Geometric
mean
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Children and adolescents
de Jongste 2009 0.00995 (0.13) 46.0 % 1.01 [ 0.78, 1.30 ]
Pijnenburg 2005 0.277 (0.12) 54.0 % 1.32 [ 1.04, 1.67 ]
Total (95% CI) 100.0 % 1.17 [ 0.98, 1.39 ]
Heterogeneity: Chi2 = 2.28, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.75 (P = 0.080)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours control Favours FeNO
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Analysis 3.1. Comparison 3 Symptom based data, Outcome 1 Symptom score.
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 3 Symptom based data
Outcome: 1 Symptom score
Study or subgroup FeNO strategy Control strategy
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Shaw 2007 52 1.1 (0.72) 51 1.15 (0.71) 52.4 % -0.07 [ -0.46, 0.32 ]
Smith 2005 46 0.4 (1.01) 48 0.6 (0.86) 47.6 % -0.21 [ -0.62, 0.19 ]
Subtotal (95% CI) 98 99 100.0 % -0.14 [ -0.42, 0.14 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Children and adolescents
Pijnenburg 2005 39 -0.1 (2.68) 46 -0.6 (2.68) 13.3 % 0.18 [ -0.24, 0.61 ]
Szefler 2008 276 21.89 (2.83) 270 21.83 (2.88) 86.7 % 0.02 [ -0.15, 0.19 ]
Subtotal (95% CI) 315 316 100.0 % 0.04 [ -0.11, 0.20 ]
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Chi2 = 1.21, df = 1 (P = 0.27), I2 =18%
-1 -0.5 0 0.5 1
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Analysis 4.1. Comparison 4 Medications, Outcome 1 ICS dose at final visit.
Review: Tailored interventions based on exhaled nitric oxide versus clinical symptoms for asthma in children and adults
Comparison: 4 Medications
Outcome: 1 ICS dose at final visit
Study or subgroup FeNO strategy Control strategy
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Shaw 2007 52 557 (670.63) 51 895 (1035.51) 45.1 % -338.00 [ -675.63, -0.37 ]
Smith 2005 46 740 (720.63) 48 1282 (792.09) 54.9 % -542.00 [ -847.91, -236.09 ]
Subtotal (95% CI) 98 99 100.0 % -450.03 [ -676.73, -223.34 ]
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.89 (P = 0.00010)
2 Children and adolescents
de Jongste 2009 75 474.67 (584.04) 71 444.37 (627.953) 31.9 % 30.30 [ -166.69, 227.29 ]
Pijnenburg 2005 39 935.4 (655.7) 46 910.4 (678.2) 15.3 % 25.00 [ -259.18, 309.18 ]
Szefler 2008 276 1120 (996) 270 880 (823) 52.8 % 240.00 [ 86.89, 393.11 ]
Subtotal (95% CI) 390 387 100.0 % 140.18 [ 28.94, 251.43 ]
Heterogeneity: Chi2 = 3.46, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 2.47 (P = 0.014)
-500 -250 0 250 500
Favours FeNO Favours control
A P P E N D I C E S
Appendix 1. Database Search Strategies
Database Search string
MEDLINE 1 exp asthma/
2 exp Bronchial Spasm/
3 asthma$.mp.
4 wheez$.mp.
5 bronchospas$.mp.
6 (bronch$ adj3 spas$).mp.
7 bronchoconstrict$.mp.
8 (bronch$ adj3 constrict$).mp.
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(Continued)
9 airway$ inflammation$.mp.
10 or/1-9
11 Nitric Oxide/
12 exhaled nitric oxide.mp.
13 nitric$.mp.
14 eno.mp.
15 feno.mp.
16 or/11-15
17 10 and 16
(Combined with RCT filter)
EMBASE 1 exp asthma/
2 Bronchospasm/
3 asthma$.mp.
4 wheez$.mp.
5 bronchospas$.mp.
6 (bronch$ adj3 spas$).mp.
7 bronchoconstrict$.mp.
8 (bronch$ adj3 constrict$).mp.
9 airway$ inflammation$.mp.
10 or/1-9
11 Nitric Oxide/
12 exhaled nitric oxide.mp.
13 nitric$.mp.
14 eno.mp.
15 feno.mp.
16 or/11-15
17 16 and 10
(combined with RCT filter)
CENTRAL #1. MeSH descriptor Asthma explode all trees
#2. MeSH descriptor Bronchial Spasm explode all trees
#3. asthma*
#4. wheez*
#5. bronchospas*
#6. bronch* near spas*
#7. bronchoconstrict*
#8. bronch* near constrict*
#9. airway* inflammation*
#10.(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11.MeSH descriptor Nitric Oxide, this term only
#12. exhaled nitric oxide
#13.nitric*
#14.eno
#15. feno
#16. (#11 OR #12 OR #13 OR #14 OR #15)
#17. (#10 AND #16)
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WH A T ’ S N E W
Last assessed as up-to-date: 27 February 2009.
Date Event Description
31 March 2009 New citation required and conclusions have changed 2 studies added with data and conclusions amended, fol-
lowing new search in February 2009. Risk of bias and sum-
mary of findings tables added
H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 2, 2008
Date Event Description
30 January 2008 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
Protocol: Written by HP and AC. AL, JAK and CT reviewed protocol
Review: All reviewed manuscript. HP and AC extracted data and performed the analysis. CJC triple checked data analysis and data
extraction.
D E C L A R A T I O N S O F I N T E R E S T
Some of the authors are currently running a RCT on this subject.
S O U R C E S O F S U P P O R T
Internal sources
• Royal Children’s Hospital Foundation, Brisbane, Australia.
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External sources
• National Health and Medical Research Council, Australia.
• Queensland Smart State Clinical Fellowship, Australia.
Support for AC
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The outcome dose of inhaled corticosteroids was added post-hoc to the review. Risk of Bias tables have been added for the 2009 update.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Adrenal Cortex Hormones [∗administration & dosage]; Anti-Asthmatic Agents [∗administration & dosage]; Asthma [∗drug therapy;
metabolism]; Biological Markers [analysis]; Breath Tests [methods]; Nitric Oxide [∗analysis]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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